OPTIMAL SCREENING FOR PROSTATE CA WITH SERIAL PSA LEVELS
通过连续 PSA 水平对前列腺 CA 进行最佳筛查
基本信息
- 批准号:2796352
- 负责人:
- 金额:$ 4.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-30 至 2000-03-29
- 项目状态:已结题
- 来源:
- 关键词:cancer risk clinical research computer simulation diagnosis design /evaluation disease /disorder model early diagnosis human subject longitudinal human study male mass screening mathematical model neoplasm /cancer classification /staging neoplasm /cancer diagnosis prostate neoplasms prostate specific antigen veterans
项目摘要
DESCRIPTION (Applicant's Description) The goal of this pilot study is to
develop an approach to early detection of carcinoma of the prostate (CP)
that is optimized, i.e. that, when compared to the standard approach,
results in the greatest increase in years of life saved for a given
increment in testing. The principal investigator is currently developing
precise statistical models of long term longitudinal PSA behavior using data
from participants in the Veterans Affairs (VA) Normative Aging Study (NAS)
as part of a currently funded study. After the distributional assumptions
of these models have been tested, we will use them to develop an optimized
early detection approach that reassesses the risk that the patient has
prostate cancer after each successive PSA measurement based on all previous
measurements. The decision for the next step, either biopsy or when to have
the next PSA test, is based on the current assessment of risk. Those at
elevated risk will be measured more frequently for PSA levels, and those at
highest risk are referred for more invasive diagnostic workup such as
biopsy. Thus, more screening resources are allocated to patients who are at
increased risk. For the intermediate risk group, time until next PSA
measurement will be optimized to maximize the expected years of life saved,
using published estimates of treatment efficacy by stage and age. The
approach will be developed in three stages: (I) A statistical method for
estimating the risk of CP based on single or multiple longitudinal PSA
levels, and the duration between the PSA levels will be developed, (II) A
computer simulation of an early detection program for CP incorporating the
method for calculating risk of CP will be written, and (III) The simulation
will be used to identify the optimal scheme for assigning patients into
normal, intermediate, and high risk categories. This program will be
similar to an approach the PI has developed for early detection of ovarian
cancer with longitudinal levels of the marker CA125. The long-term
objectives, beyond the scope of this proposal, are to expand these
approaches to early detection of CP to include other tests such as "free
PSA" and digital rectal exam, to implement these approaches in software
appropriate for use in clinical settings, and to compare such optimized
screening strategies with current screening strategies in a randomized
clinical trial.
描述(申请人的描述)这项初步研究的目的是
开发早期发现前列腺癌(CP)的方法
这是优化的,即,与标准方法相比,
结果最大限度地增加了为给定的
测试中的增量。首席调查员目前正在开发
使用数据建立长期纵向PSA行为的精确统计模型
来自退伍军人事务部(VA)标准老龄化研究(NAS)的参与者
作为目前资助的一项研究的一部分。在分布假设之后
对这些模型进行了测试,我们将利用它们来开发一个优化的
重新评估患者存在的风险的早期检测方法
前列腺癌后每一次连续测量PSA基于所有以前的
测量。下一步的决定,无论是活组织检查还是何时进行
下一次PSA测试将基于当前的风险评估。那些位于
增加的风险将更频繁地测量PSA水平,以及
风险最高的是更具侵入性的诊断检查,例如
活组织检查。因此,更多的筛查资源被分配给处于
风险增加。对于中等风险组,到下一次PSA的时间
测量将进行优化,以最大限度地延长预期寿命,
使用已发表的按分期和年龄划分的治疗效果估计。这个
将分三个阶段制定办法:(1)统计方法
基于单个或多个纵向PSA的慢性前列腺炎风险评估
将制定PSA级别之间的持续时间,(二)A
CP早期检测程序的计算机模拟
将编写CP风险的计算方法,以及(Iii)模拟
将用于确定最佳方案,以便将患者分配到
正常、中等和高风险类别。这一计划将是
与PI开发的用于卵巢早期检测的方法类似
标记物CA125纵向水平的癌症。长期的
超出本提案范围的目标是扩大这些
早期检测CP的方法包括其他测试,如“FREE”
PSA“和直肠指诊,以便在软件中实施这些方法
适合在临床环境中使用,并比较这种优化
筛查策略与当前筛查策略的随机化
临床试验。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven J Skates其他文献
Importance of tumor size and repopulation for radiocurability of skin cancer.
肿瘤大小和增殖对于皮肤癌放射治疗的重要性。
- DOI:
- 发表时间:
1993 - 期刊:
- 影响因子:0
- 作者:
Maciejewski Ba;Steven J Skates;A. Zajusz;D. Lange - 通讯作者:
D. Lange
Steven J Skates的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven J Skates', 18)}}的其他基金
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls
对病例和对照中的系列诊断前 PLCO 血清进行蛋白质组学分析,以识别早期检测卵巢癌生物标志物,这些生物标志物在大部分病例中上升,而在大多数对照中保持稳定
- 批准号:
10703252 - 财政年份:2021
- 资助金额:
$ 4.6万 - 项目类别:
Novel Serum, Plasma, and Urine Biomarkers of Ovarian Can
卵巢癌的新型血清、血浆和尿液生物标志物
- 批准号:
6991022 - 财政年份:2004
- 资助金额:
$ 4.6万 - 项目类别:
MEASURING AND STATISTICAL MODELING OF SERIAL PSA LEVELS
系列 PSA 水平的测量和统计建模
- 批准号:
2733338 - 财政年份:1997
- 资助金额:
$ 4.6万 - 项目类别:
OPTIMAL SCREENING FOR PROSTATE CA WITH SERIAL PSA LEVELS
通过连续 PSA 水平对前列腺 CA 进行最佳筛查
- 批准号:
2552697 - 财政年份:1997
- 资助金额:
$ 4.6万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别: